https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-21 / Oncol Lett 2017 Jun;13(6):4959-4964
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-21 / Oncol Lett 2017 Jun;13(6):4959-49642017-04-21 00:00:002017-04-21 00:00:00Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-20 / Oncoimmunology 2017;6(6):e1319044
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-20 / Oncoimmunology 2017;6(6):e13190442017-04-20 00:00:002019-02-15 08:46:16Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-07 / J Hematol Oncol 2017 04;10(1):82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-07 / J Hematol Oncol 2017 04;10(1):822017-04-07 00:00:002019-02-15 08:52:39Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-17 / Therap Adv Gastroenterol 2017 Jan;10(1):168-194
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-17 / Therap Adv Gastroenterol 2017 Jan;10(1):168-1942016-10-17 00:00:002016-10-17 00:00:00Immunotherapy in pancreatic cancer treatment: a new frontier
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14579)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14579)2016-06-03 00:00:002016-06-03 00:00:00A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14586)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / J Clin Oncol 34, 2016 (suppl; abstr e14586)2016-06-03 00:00:002016-06-03 00:00:00Dendritic cell vaccine transduced with ubiquitin-mesothelin fusion gene for pancreatic cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-04 / Cancer Sci. 2016 Apr;107(4):514-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-04 / Cancer Sci. 2016 Apr;107(4):514-202016-03-04 00:00:002016-03-04 00:00:00Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-14 / World J. Gastroenterol. 2016 Jan;22(2):748-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-14 / World J. Gastroenterol. 2016 Jan;22(2):748-632016-01-14 00:00:002016-01-14 00:00:00Viro-immune therapy: A new strategy for treatment of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-16 / Mol. Cancer 2015 Dec;14:210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-16 / Mol. Cancer 2015 Dec;14:2102015-12-16 00:00:002015-12-16 00:00:00Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-29 / Oncotarget 2015 Sep;6(29):27751-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-29 / Oncotarget 2015 Sep;6(29):27751-622015-09-29 00:00:002019-02-15 08:52:37Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4
